Inventiva (NASDAQ:IVA) Sees Unusually-High Trading Volume - Still a Buy?

Key Points

• Inventiva’s trading volume increased 19% to approximately 890,467 shares, while the stock traded near $3.26.
• Analyst sentiment is broadly positive: the stock has a consensus “Buy” rating and a $15.75 average price target, despite one “Sell” rating. Guggenheim also raised its target to $14.
• Institutional investors own 19.06% of Inventiva, with several hedge funds recently initiating or increasing positions. The company is developing lanifibranor, a late-stage candidate for MASH and related liver disease.

Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Get Free Report) shares saw an uptick in trading volume on Friday. Approximately 890,467 shares were traded during trading, an increase of 19% from the previous session's volume of 751,098 shares. The stock last traded at $3.2550 and had previously closed at $3.26.

Analysts Set New Price Targets

Several equities analysts have issued reports on IVA shares. Guggenheim raised their price objective on Inventiva from $11.00 to $14.00 and gave the stock a "buy" rating in a report on Tuesday, September 15th. Cantor Fitzgerald started coverage on Inventiva in a report on Friday, July 17th. They issued an "overweight" rating for the company. Piper Sandler restated an "overweight" rating on shares of Inventiva in a research note on Wednesday, September 16th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Inventiva in a research report on Friday, July 17th. Three analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus price target of $15.75.

Inventiva Stock Performance

The company's 50-day simple moving average is $4.45 and its 200-day simple moving average is $4.77.

Hedge Funds Weigh In On Inventiva

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Engineers Gate Manager LP increased its position in Inventiva by 155.5% in the 2nd quarter. Engineers Gate Manager LP now owns 71,116 shares of the company's stock valued at $269,000 after acquiring an additional 43,280 shares during the period. Seven Fleet Capital Management LP acquired a new position in shares of Inventiva in the first quarter valued at approximately $1,111,000. Persistent Asset Partners Ltd purchased a new stake in shares of Inventiva during the fourth quarter worth approximately $603,000. NEXTBio Capital Management LP acquired a new stake in shares of Inventiva during the fourth quarter worth $6,039,000. Finally, Eventide Asset Management LLC acquired a new stake in shares of Inventiva during the fourth quarter worth $1,155,000. Hedge funds and other institutional investors own 19.06% of the company's stock.

About Inventiva

Inventiva SA is a clinical-stage biopharmaceutical company headquartered in Daix, France. The company develops small-molecule therapies for metabolic, liver and autoimmune diseases, with a focus on conditions that have limited treatment options.

Inventiva's lead product candidate is lanifibranor, an oral pan-PPAR agonist being developed for metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH). The investigational therapy is intended to address liver inflammation and fibrosis associated with the disease and is being evaluated in late-stage clinical development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.